IL304123A - RNA transfer preparations and methods - Google Patents
RNA transfer preparations and methodsInfo
- Publication number
- IL304123A IL304123A IL304123A IL30412323A IL304123A IL 304123 A IL304123 A IL 304123A IL 304123 A IL304123 A IL 304123A IL 30412323 A IL30412323 A IL 30412323A IL 304123 A IL304123 A IL 304123A
- Authority
- IL
- Israel
- Prior art keywords
- rna
- delivery
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063131528P | 2020-12-29 | 2020-12-29 | |
| PCT/US2021/065386 WO2022147039A1 (en) | 2020-12-29 | 2021-12-28 | Compositions and methods for delivery of rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304123A true IL304123A (en) | 2023-09-01 |
Family
ID=82261084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304123A IL304123A (en) | 2020-12-29 | 2023-06-28 | RNA transfer preparations and methods |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250263678A1 (https=) |
| EP (1) | EP4271389A4 (https=) |
| JP (1) | JP2024501388A (https=) |
| CN (1) | CN116916936A (https=) |
| AU (1) | AU2021413753A1 (https=) |
| CA (1) | CA3206970A1 (https=) |
| IL (1) | IL304123A (https=) |
| WO (1) | WO2022147039A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024094211A1 (zh) * | 2022-11-06 | 2024-05-10 | 斯微(上海)生物科技股份有限公司 | 一种脂质组合物 |
| EP4692345A1 (en) * | 2023-03-29 | 2026-02-11 | Shenzhen Shenxin Biotechnology Co., Ltd. | Polynucleotide molecule comprising poly(a) and use thereof |
| WO2025049632A1 (en) * | 2023-08-29 | 2025-03-06 | Rejuvenation Technologies Inc. | Compositions and methods for broad delivery of rna to tissue |
| JP2026066951A (ja) * | 2024-10-07 | 2026-04-17 | Agc株式会社 | 核酸送達用脂質ナノ粒子 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3047667T3 (en) * | 2013-02-22 | 2025-12-04 | Univ Leland Stanford Junior | Methods relating to telomere extension |
| EP3087193A4 (en) * | 2013-12-27 | 2017-08-09 | Teloregen, Inc. | Compositions and methods for providing active telomerase to cells in vivo |
| US20180360924A1 (en) * | 2015-11-25 | 2018-12-20 | The Methodist Hospital System | Telomere extension and anti-inflammatory agents for cell regeneration |
| JP2019529499A (ja) * | 2016-09-30 | 2019-10-17 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 組織指向性発現を用いた抗体ベースの遺伝子治療 |
| WO2019188867A1 (ja) * | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| JP7304421B2 (ja) * | 2018-10-05 | 2023-07-06 | アールエヌエージーン インコーポレイテッド | 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途 |
| CA3118034A1 (en) * | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
| EP3906039A4 (en) * | 2019-01-04 | 2023-01-18 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
-
2021
- 2021-12-28 EP EP21916372.2A patent/EP4271389A4/en active Pending
- 2021-12-28 AU AU2021413753A patent/AU2021413753A1/en active Pending
- 2021-12-28 US US18/270,179 patent/US20250263678A1/en active Pending
- 2021-12-28 WO PCT/US2021/065386 patent/WO2022147039A1/en not_active Ceased
- 2021-12-28 CN CN202180094678.9A patent/CN116916936A/zh active Pending
- 2021-12-28 JP JP2023563917A patent/JP2024501388A/ja active Pending
- 2021-12-28 CA CA3206970A patent/CA3206970A1/en active Pending
-
2023
- 2023-06-28 IL IL304123A patent/IL304123A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4271389A4 (en) | 2026-04-08 |
| US20250263678A1 (en) | 2025-08-21 |
| AU2021413753A1 (en) | 2023-07-13 |
| JP2024501388A (ja) | 2024-01-11 |
| WO2022147039A1 (en) | 2022-07-07 |
| CA3206970A1 (en) | 2022-07-07 |
| EP4271389A1 (en) | 2023-11-08 |
| CN116916936A (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2605312B (en) | Compositions and methods for delivery of RNA | |
| GB2613225B (en) | Compositions and methods for targeted RNA delivery | |
| IL304123A (en) | RNA transfer preparations and methods | |
| EP4380576A4 (en) | Compositions and methods for targeted rna delivery | |
| IL308746A (en) | Cyclic RNA compositions and methods | |
| EP3965780A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE | |
| GB2592505B (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| GB2600800B (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| EP4117684A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED RELEASE OF ANTIVIRAL ACTIVE INGREDIENTS | |
| AU2021413753A9 (en) | Compositions and methods for delivery of rna | |
| EP4240248A4 (en) | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTICS USING CARRIERS | |
| IL309175A (en) | Methods and preparations for targeting PD-L1 | |
| IL318761A (en) | Oligonucleotide compositions and methods thereof | |
| EP4415690A4 (en) | COMPOSITIONS AND PROCEDURES FOR THE DISPENSING OF FUNDS | |
| IL325571A (en) | Oligonucleotide compositions and methods thereof | |
| IL316504A (en) | RNA compositions for the delivery of monkeypox antigens and related methods | |
| EP3788141A4 (en) | COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY | |
| IL316714A (en) | Oligonucleotide compositions and methods therefor | |
| IL319195A (en) | Compositions and methods for RNA delivery | |
| IL318499A (en) | Compounds for targeted lysosomal degradation and methods of using them | |
| IL318437A (en) | Compositions containing oligonucleotides, and methods of using them | |
| EP4352218A4 (en) | COMPOSITIONS AND METHODS FOR THE TARGETED RELEASE OF THERAPEUTICS | |
| HK40112368A (en) | Compositions and methods for targeted rna delivery | |
| HK40078031A (en) | Compositions and methods for enhanced delivery of agents | |
| IL314715A (en) | Methods and compositions for targeted administration of intracellular biological agents |